Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.26USD
4:00pm EDT
Change (% chg)

$-0.00 (-0.66%)
Prev Close
$0.26
Open
$0.27
Day's High
$0.28
Day's Low
$0.26
Volume
152,745
Avg. Vol
264,789
52-wk High
$1.63
52-wk Low
$0.24

Select another date:

Thu, May 17 2018

BRIEF-Trovagene Completes First Dosing Cohort Of Patients In Phase 1B/2 Trial Of PCM-075

* TROVAGENE ANNOUNCES COMPLETION OF FIRST DOSING COHORT OF PATIENTS IN ONGOING PHASE 1B/2 TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage:

BRIEF-Trovagene Files For Offering Of Up To $15 Mln Of Class A Units Of Common Stock And Up To $15 Mln Of Class B Units Of Common Stock

* TROVAGENE INC FILES FOR OFFERING OF UP TO $15.0 MILLION OF CLASS A UNITS OF COMMON STOCK AND UP TO $15.0 MILLION OF CLASS B UNITS OF COMMON STOCK - SEC FILING Source text: [https://bit.ly/2rAnkbg] Further company coverage:

BRIEF-Trovagene Reports Q1 Loss Per Share $0.09

* TROVAGENE ANNOUNCES FIRST QUARTER 2018 HIGHLIGHTS AND FINANCIAL RESULTS

BRIEF-Trovagene Reports Q4 Loss Per Share $0.06

* TROVAGENE ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 RESULTS

BRIEF-Trovagene Completes Cycle-One Dosing In First Patient Enrolled In Phase 1B/2 Clinical Trial Of PCM-075

* TROVAGENE ANNOUNCES COMPLETION OF CYCLE-ONE DOSING IN FIRST PATIENT ENROLLED IN ITS PHASE 1B/2 CLINICAL TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:

BRIEF-Trovagene Initiates Unite Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate Cancer

* TROVAGENE ANNOUNCES INITIATION OF UNITE PHASE 2 CLINICAL TRIAL OF PCM-075 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) Source text for Eikon: Further company coverage:

BRIEF-Trovagene Prices $4.5 Million Public Offering

* PRICING OF PUBLIC OFFERING OF 15 MILLION SHARES OF ITS COMMON STOCK, COMMON WARRANTS TO PURCHASE UP TO 15 MILLION SHARES OF COMMON STOCK

BRIEF-Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®

* TROVAGENE SUBMITS PROTOCOL TO FDA FOR PHASE 2 CLINICAL TRIAL OF PCM-075 IN COMBINATION WITH ZYTIGA® FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

BRIEF-Trovagene's preclinical data to be featured at San Antonio Breast Cancer Symposium

* TROVAGENE PRESENTS DATA SHOWING SENSITIVITY OF TRIPLE NEGATIVE BREAST CANCER (TNBC) CELL LINES TO PCM-075 AND SYNERGY WITH ZYTIGA® AT SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) Source text for Eikon: Further company coverage:

Select another date: